Myopia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Myopia Market Outlook

Thelansis’s “Myopia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myopia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Myopia Overview

Myopia occurs when the focused image is too close to the eye's retinal photoreceptor layer. Myopia is classified into two types. The simple, less severe conditions are also known as physiological or school myopia, and they occur as a result of the correlative failure of the normal eye's refractive components. It can also be caused by an increase in the curvature of the surface of the cornea or lens and an increase in the axial diameter of the eye. Myopia of up to – 6.0 D is involved. Pathological, degenerative, malignant, or high myopia is a rare form that causes progressive elongation of the globe and accompanying stretching of the scleral wall, resulting in a high refractive error of – 6 D or higher. High myopia frequently causes choroid atrophy and subsequent retinal macular degeneration, resulting in loss of central visual acuity and an increased risk of retinal detachment, glaucoma, and strabismus. High myopia is a significant cause of legal blindness in many developed countries. However, genetic and environmental factors that have been implicated in the etiology of myopia remain to be known.

• The prevalence of patient pool of myopia varies from 90 MN to 100 MN in the USA, with a male and female ratio of 46% and 54%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: